Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

BACKGROUND: Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve ease of administration. With knowledge of nivoluma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., Bello, A., Roy, A., Agrawal, S.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Original articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834087/
https://ncbi.nlm.nih.gov/pubmed/28520840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx235
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares